Effect of augmenting cholinergic function on gait and balance

Martina Mancini, Brett W Fling, Anne Gendreau, Jodi Lapidus, Fay B Horak, Kathy Chung, John G Nutt, Martina Mancini, Brett W Fling, Anne Gendreau, Jodi Lapidus, Fay B Horak, Kathy Chung, John G Nutt

Abstract

Background: Impaired mobility and falls are clinically important complications of Parkinson's disease (PD) and a major detractor from quality of life for which there are limited therapies. Pathological, neuroimaging and clinical evidence suggest that degeneration of cholinergic systems may contribute to impairments of balance and gait in PD. The proposed trial will examine the effects of augmentation of the cholinergic system on balance and gait.

Design: The study is a single-site, proof of concept, randomized, double-blind, cross-over trial in patients with PD. Each treatment period will be 6 weeks with a 6-week washout between treatments for a total of 18 weeks for each subject. Donepezil in 2.5 mg capsules or identical appearing placebo capsules will be increased from two per day (5 mg) to four capsules (10 mg) after 3 weeks, if tolerated. Subjects will have idiopathic Parkinson's disease, Hoehn and Yahr stages 2 to 4. We anticipate recruiting up to 100 subjects for screening to have 54 enrolled and 44 subjects complete both phases of treatment. Dropouts will be replaced. As this is a crossover trial, all subjects will be exposed to both donepezil and to placebo. The primary outcome measures will be the root mean square of the mediolateral sway when standing and the variability of the stride duration when walking for two minutes. Secondary outcomes will be the computerized Attention Network Test to examine three domains of attention and the Short-latency Afferent Inhibition (SAI), a physiological marker obtained with transcranial magnetic stimulation as a putative marker of cholinergic activity.

Discussion: The results of this study will be the most direct test of the hypothesized role of cholinergic neurotransmission in gait and balance. The study is exploratory because we do not know whether donepezil will affect gait, balance or attention, nor which measures of gait, balance or attention will be sensitive to drug manipulation. We hypothesize that change in cholinergic activity, as measured with SAI, will predict the relative effectiveness of donepezil on gait and balance. Our immediate goal is to determine the potential utility of cholinergic manipulation as a strategy for preventing or treating balance and gait dysfunction in PD. The findings of this trial are intended to lead to more sharply focused questions about the role of cholinergic neurotransmission in balance and gait and eventually to Phase II B trials to determine clinical utility of cholinergic manipulation to prevent falls and improve mobility.

Trial registration: This trial is registered at clinical trials.gov ( NCT02206620).

Figures

Fig. 1
Fig. 1
Study design and outcomes measures for each phase of the study

References

    1. Kang GA, Bronstein JM, Masterman DL, Redelings M, Crum JA, Ritz B. Clinical characteristics in early Parkinson’s disease in a central California population-based study. Mov Disord. 2005;20:1133–42. doi: 10.1002/mds.20513.
    1. Pickering RM, Grimbergen YA, Rigney U, Ashburn A, Mazibrada G, Wood B, et al. A meta-analysis of six prospective studies of falling in Parkinson’s disease. Mov Disord. 2007;22:1892–900. doi: 10.1002/mds.21598.
    1. Wood BH, Bilclough JA, Bowron A, Walker RW. Incidence and prediction of falls in Parkinson’s disease: a prospective multidisciplinary study. J Neurol Neurosurg Psychiatry. 2002;72:721–5. doi: 10.1136/jnnp.72.6.721.
    1. Johnell O, Melton LJ, 3rd, Atkinson EJ, O’Fallon WM, Kurland LT. Fracture risk in patients with parkinsonism: a population-based study in Olmsted County, Minnesota. Age Ageing. 1992;21:32–8. doi: 10.1093/ageing/21.1.32.
    1. Adkin AL, Frank JS, Jog MS. Fear of falling and postural control in Parkinson’s disease. Mov Disord. 2003;18:496–502. doi: 10.1002/mds.10396.
    1. Muslimovic D, Post B, Speelman JD, Schmand B, de Haan RJ, Group CS. Determinants of disability and quality of life in mild to moderate Parkinson disease. Neurology. 2008;70:2241–7. doi: 10.1212/01.wnl.0000313835.33830.80.
    1. Bryant MS, Rintala DH, Hou JG, Charness AL, Fernandez AL, Collins RL, et al. Gait variability in Parkinson’s disease: influence of walking speed and dopaminergic treatment. Neurol Res. 2011;33:959–64. doi: 10.1179/1743132811Y.0000000044.
    1. Curtze C, Nutt JG, Carlson-Kuhta P, Mancini M, Horak FB. Levodopa is a double-edged sword for balance and gait in people with Parkinson’s disease. Mov Disord. 2015;30:1361–70. doi: 10.1002/mds.26269.
    1. Horak FB, Nutt JG, Nashner LM. Postural inflexibility in parkinsonian subjects. J Neurol Sci. 1992;111:46–58. doi: 10.1016/0022-510X(92)90111-W.
    1. Lord S, Baker K, Nieuwboer A, Burn D, Rochester L. Gait variability in Parkinson’s disease: an indicator of non-dopaminergic contributors to gait dysfunction? J Neurol. 2011;258:566–72. doi: 10.1007/s00415-010-5789-8.
    1. St George RJ, Nutt JG, Burchiel KJ, Horak FB. A meta-regression of the long-term effects of deep brain stimulation on balance and gait in PD. Neurology. 2010;75:1292–9. doi: 10.1212/WNL.0b013e3181f61329.
    1. Rinne JO, Ma SY, Lee MS, Collan Y, Roytta M. Loss of cholinergic neurons in the pedunculopontine nucleus in Parkinson’s disease is related to disability of the patients. Parkinsonism Relat Disord. 2008;14:553–7. doi: 10.1016/j.parkreldis.2008.01.006.
    1. Bohnen NI, Frey KA, Studenski S, Kotagal V, Koeppe RA, Scott PJ, et al. Gait speed in Parkinson disease correlates with cholinergic degeneration. Neurology. 2013;81:1611–6. doi: 10.1212/WNL.0b013e3182a9f558.
    1. Bohnen NI, Kaufer DI, Hendrickson R, Ivanco LS, Lopresti BJ, Constantine GM, et al. Cognitive correlates of cortical cholinergic denervation in Parkinson’s disease and parkinsonian dementia. J Neurol. 2006;253:242–7. doi: 10.1007/s00415-005-0971-0.
    1. Bohnen NI, Muller ML, Koeppe RA, Studenski SA, Kilbourn MA, Frey KA, et al. History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology. 2009;73:1670–6. doi: 10.1212/WNL.0b013e3181c1ded6.
    1. Karachi C, Grabli D, Bernard FA, Tande D, Wattiez N, Belaid H, et al. Cholinergic mesencephalic neurons are involved in gait and postural disorders in Parkinson disease. J Clin Invest. 2010;120:2745–54. doi: 10.1172/JCI42642.
    1. Chung KA, Lobb BM, Nutt JG, Horak FB. Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease. Neurology. 2010;75:1263–9. doi: 10.1212/WNL.0b013e3181f6128c.
    1. Litvinenko IV, Odinak MM, Mogil’naya VI, Emelin AY. Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson’s disease (an open controlled trial) Neurosci Behav Physiol. 2008;38:937–45. doi: 10.1007/s11055-008-9077-3.
    1. HIller AP, Nutt JG, Mancini M, Horak FB, Kareus S, Schoneburg BM, et al. Are cholinesterase inhibitors effective in improving balance in Parkinson’s disease? J Neurol Disord. 2015; In press
    1. Dubois B, Tolosa E, Katzenschlager R, Emre M, Lees AJ, Schumann G, et al. Donepezil in Parkinson’s disease dementia: a randomized, double-blind efficacy and safety study. Mov Disord. 2012;27:1230–8. doi: 10.1002/mds.25098.
    1. Chung KA, Lobb BM, Nutt JG, McNames J, Horak F. Objective measurement of dyskinesia in Parkinson’s disease using a force plate. Mov Disord. 2010;25:602–8. doi: 10.1002/mds.22856.
    1. Chou KL, Amick MM, Brandt J, Camicioli R, Frei K, Gitelman D, et al. A recommended scale for cognitive screening in clinical trials of Parkinson’s disease. Mov Disord. 2010;25:2501–7. doi: 10.1002/mds.23362.
    1. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23:2129–70. doi: 10.1002/mds.22340.
    1. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695–9. doi: 10.1111/j.1532-5415.2005.53221.x.
    1. Powell LE, Myers AM. The Activities-specific Balance Confidence (ABC) Scale. J Gerontol A Biol Sci Med Sci. 1995;50A:M28–34. doi: 10.1093/gerona/50A.1.M28.
    1. Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The Parkinson’s Disease Questionnaire (PDQ-39): development and validation of a Parkinson’s disease summary index score. Age Ageing. 1997;26:353–7. doi: 10.1093/ageing/26.5.353.
    1. Hausdorff JM. Gait variability: methods, modeling and meaning. J Neuroeng Rehabil. 2005;2:19. doi: 10.1186/1743-0003-2-19.
    1. Fan J, Gu X, Guise KG, Liu X, Fossella J, Wang H, et al. Testing the behavioral interaction and integration of attentional networks. Brain Cogn. 2009;70:209–20. doi: 10.1016/j.bandc.2009.02.002.
    1. Fan J, McCandliss BD, Fossella J, Flombaum JI, Posner MI. The activation of attentional networks. Neuroimage. 2005;26:471–9. doi: 10.1016/j.neuroimage.2005.02.004.
    1. Tokimura H, Di Lazzaro V, Tokimura Y, Oliviero A, Profice P, Insola A, et al. Short latency inhibition of human hand motor cortex by somatosensory input from the hand. J Physiol. 2000;523(Pt 2):503–13. doi: 10.1111/j.1469-7793.2000.t01-1-00503.x.
    1. Rochester L, Yarnall AJ, Baker MR, David RV, Lord S, Galna B, et al. Cholinergic dysfunction contributes to gait disturbance in early Parkinson’s disease. Brain. 2012;135:2779–88. doi: 10.1093/brain/aws207.
    1. Di Lazzaro V, Oliviero A, Profice P, Pennisi MA, Di Giovanni S, Zito G, et al. Muscarinic receptor blockade has differential effects on the excitability of intracortical circuits in the human motor cortex. Exp Brain Res. 2000;135:455–61. doi: 10.1007/s002210000543.
    1. Nardone R, Florio I, Lochner P, Tezzon F. Cholinergic cortical circuits in Parkinson’s disease and in progressive supranuclear palsy: a transcranial magnetic stimulation study. Exp Brain Res. 2005;163:128–31. doi: 10.1007/s00221-005-2228-7.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever